• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression ect treatment for depression and anxiety

For many people gripped by depression, traditional therapies and medication are ineffective. The individual approach to treatment could be the answer.

Cue is an intervention platform for digital devices that translates passively acquired normal smartphone sensor data into personalized micro-interventions to improve mental health. We analysed the best-fit personalized ML models for each subject using Shapley values to understand their feature predictors and uncover distinct features that deterministically change mood as time passes.

Predictors of Mood

Depression is among the most prevalent causes of mental illness.1 Yet, only half of people suffering from the disorder receive treatment1. To improve the outcomes, clinicians need to be able to identify and treat patients who have the highest probability of responding to specific treatments.

A customized depression treatment is one method to achieve this. Researchers at the University of Illinois Chicago are developing new methods to predict which patients will gain the most from certain treatments. They are using mobile phone sensors as well as a voice assistant that incorporates artificial intelligence, and other digital tools. Two grants totaling more than $10 million will be used to discover biological and behavioral indicators of response.

The majority of research to the present has been focused on clinical and sociodemographic characteristics. These include demographics like gender, age and education as well as clinical characteristics such as symptom severity and comorbidities, as well as biological markers.

A few studies have utilized longitudinal data in order to predict mood in individuals. Many studies do not take into consideration the fact that mood can vary significantly between individuals. Therefore, it is crucial to develop methods that allow for the identification of different mood predictors for each person and the effects of treatment.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This enables the team to create algorithms that can detect distinct patterns of behavior and emotions that vary between individuals.

In addition to these methods, the team created a machine learning algorithm to model the changing variables that influence each person's mood. The algorithm integrates the individual differences to produce a unique "digital genotype" for each participant.

This digital phenotype was linked to CAT DI scores that are a psychometrically validated symptoms severity scale. However, the correlation was weak (Pearson's r = 0.08, BH-adjusted P-value of 3.55 1003) and varied widely across individuals.

Predictors of symptoms

Depression is the leading cause of disability around the world1, however, it is often not properly diagnosed and treated. Depressive disorders are often not treated because of the stigma associated with them and the lack of effective treatments.

To allow for individualized treatment in order to provide a more personalized treatment, identifying factors that predict the severity of symptoms is crucial. However, the current methods for predicting symptoms depend on the clinical interview which is unreliable and only detects a limited number of symptoms that are associated with depression.2

Machine learning can be used to combine continuous digital behavioral phenotypes captured by smartphone sensors and an online mental health tracker (the Computerized Adaptive Testing Depression Inventory CAT-DI) along with other indicators of severity of symptoms can improve diagnostic accuracy and increase the effectiveness of treatment for depression. Digital phenotypes permit continuous, high-resolution measurements and capture a variety of distinct behaviors and patterns that are difficult to capture through interviews.

The study involved University of California Los Angeles (UCLA) students who were suffering from mild to severe depression symptoms. enrolled in the Screening and non drug treatment for depression for anxiety depression treatment and Depression (STAND) program29 that was created under the UCLA Depression Grand Challenge. Participants were routed to online support or in-person clinical care depending on their depression severity. Participants with a CAT-DI score of 35 or 65 were allocated online support via a peer coach, while those with a score of 75 were sent to in-person clinical care for psychotherapy.

At baseline, participants provided an array of questions regarding their personal demographics and psychosocial characteristics. These included age, sex, education, work, and financial status; if they were divorced, partnered or single; their current suicidal thoughts, intentions or attempts; and the frequency at the frequency they consumed alcohol. The CAT-DI was used for assessing the severity of depression treatment resistant-related symptoms on a scale ranging from zero to 100. The CAT-DI tests were conducted every other week for the participants who received online support and once a week for those receiving in-person support.

Predictors of Treatment Response

Research is focusing on personalization of treatment for depression. Many studies are focused on finding predictors, which can help doctors determine the most effective medications to treat each patient. Pharmacogenetics, for instance, identifies genetic variations that determine how the human body metabolizes drugs. This allows doctors to select drugs that are likely to be most effective for each patient, reducing the time and effort in trial-and-error procedures and avoiding side effects that might otherwise slow advancement.

Another promising method is to construct prediction models using multiple data sources, including clinical information and neural imaging data. These models can be used to identify which variables are the most likely to predict a specific outcome, such as whether a medication can improve symptoms or mood. These models can be used to determine the response of a patient to a treatment they are currently receiving which allows doctors to maximize the effectiveness of current treatment.

A new generation employs machine learning methods such as supervised and classification algorithms such as regularized logistic regression, and tree-based methods to combine the effects of several variables and improve predictive accuracy. These models have shown to be useful for predicting treatment outcomes such as the response to antidepressants. These models are getting more popular in psychiatry, and it is expected that they will become the norm for future clinical practice.

Research into the underlying causes of depression continues, as well as predictive models based on ML. Recent research suggests that the disorder is linked with neural dysfunctions that affect specific circuits. This suggests that an the treatment for depression will be individualized focused on therapies that target these neural circuits to restore normal function.

Internet-delivered interventions can be an option to accomplish this. They can offer a more tailored and individualized experience for patients. One study found that an internet-based program improved symptoms and provided a better quality life for MDD patients. Additionally, a randomized controlled trial of a personalized approach to depression treatment showed sustained improvement and reduced side effects in a significant proportion of participants.

Predictors of side effects

A major issue in personalizing depression treatment is predicting the antidepressant medications that will have very little or no side effects. Many patients experience a trial-and-error approach, using various medications prescribed before finding one that is safe and effective. Pharmacogenetics is an exciting new method for an efficient and targeted approach to selecting antidepressant treatments.

There are several variables that can be used to determine which antidepressant should be prescribed, such as gene variations, phenotypes of the patient like gender or ethnicity, and the presence of comorbidities. However it is difficult to determine the most reliable and accurate predictive factors for a specific treatment will probably require randomized controlled trials of significantly larger numbers of participants than those normally enrolled in clinical trials. This is due to the fact that it can be more difficult to identify interactions or moderators in trials that contain only one episode per person rather than multiple episodes over time.

Furthermore, the prediction of a patient's reaction to a particular medication will also likely require information about comorbidities and symptom profiles, in addition to the patient's prior subjective experiences with the effectiveness and tolerability of the medication. Currently, only some easily assessable sociodemographic and clinical variables seem to be correlated with response to MDD factors, including age, gender race/ethnicity, BMI, the presence of alexithymia, and the severity of depression symptoms.

The application of pharmacogenetics in treatment for depression is in its early stages, and many challenges remain. First, it is essential to be able to comprehend and understand the definition of the genetic factors that cause depression, as well as a clear definition of an accurate predictor of treatment response. Ethics, such as privacy, and the ethical use of genetic information must also be considered. Pharmacogenetics could, in the long run, reduce stigma surrounding mental health treatments and improve private treatment for depression outcomes. However, as with any approach to psychiatry careful consideration and application is necessary. At present, it's best to offer patients an array of depression medications that are effective and encourage them to speak openly with their doctors.